Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aggressive B-cell lymphoma: chasing the target.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research - 1 Feb 2020

Walewski Jan

Abstract excerpt

One of the first achievements of molecular biology in lymphoma science was a discovery of cell of origin (COO) classification around 20 years ago with defining activated B-cell like (ABC) and germinal center B-cell like subtypes of diffuse large B-cell lymphoma (DLBCL) with the use of gene expression profiling. These categories were considered important as seemed to present different biology, response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lymphoma, B-Cell
Share to Prednisone
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Drug Delivery Systems

Share to Randomized Controlled Trials as Topic

Share to Rituximab

Share to Vincristine

Source

Identifiers

PMID: 31672721
DOI: 10.1136/jim-2019-001169

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aggressive B-cell lymphoma: chasing the target.PMID 31672721Read ↗

Aggressive B-cell lymphomas—from morphology to molecular pathogenesisSemantic proximity Read ↗

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?Semantic proximity Read ↗

[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].Semantic proximity Read ↗

Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.Semantic proximity Read ↗

Lymphoma: turning biology into cures.Semantic proximity Read ↗

Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?Semantic proximity Read ↗

Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?Semantic proximity Read ↗

Novel therapeutic targets in diffuse large B-cell lymphomaSemantic proximity Read ↗

Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular PhenotypeSemantic proximity Read ↗

Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapySemantic proximity Read ↗

Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.